Table 2.
Tyrosine hydroxylase (TH) in brain and peripheral organs in the rat 3 days after intravenous injection of gene therapy with TH expression plasmids driven by either the SV40 promoter (clone 877) or the Gfap promoter (clone 951), respectively.
| Organs | Saline (pmol/hr/mgp) | TfRMAb-THL/877 (pmol/hr/mgp) | TfRMAb-THL/951 (pmol/hr/mgp) |
|---|---|---|---|
| Ipsilateral striatum | 128 ± 27 | 5177 ± 446* | 5536 ± 395* |
| Contralateral striatum | 6445 ± 523 | 5832 ± 391 | 5713 ± 577 |
| Ipsilateral cortex | 176 ± 30 | 132 ± 16 | 184 ± 38 |
| Contralateral cortex | 150 ± 36 | 150 ± 24 | 135 ± 25 |
| Heart | 29 ± 3 | 45 ± 8 | 31 ± 3 |
| Liver | 13 ± 2 | 130 ± 28** | 18 ± 6 |
| Lung | 42 ± 13 | 74 ± 22 | 30 ± 6 |
| Kidney | 24 ± 2 | 35 ± 5 | 31 ± 8 |
*P < 0.01 difference from saline group (ANOVA with Bonferroni correction; n = 4 rats per group). Rats were lesioned with intracerebral injections of 6-hydroxydopamine; 3 weeks after toxin injection, the rats were tested for apomorphine-induced rotation behavior; those rats testing positively to apomorphine were selected for gene therapy, which was administered intravenously 4 weeks after toxin administration; all animals were euthanized 3 days after gene administration. From [30].